Colorectal Cancer

An analysis of immunologic biomarkers in a phase II trial of patients with advanced colorectal cancer treated with chemotherapy and PD-1 checkpoint inhibition identified several factors associated with a patient’s beneficial response to the chemo-immunotherapy regimen, according to findings presented during the 33rd Annual Meeting of the Society for Immunotherapy of Cancer.

Matthew Farren, PhD, post-doctoral fellow, Winship Cancer Institute, Emory University, discusses immunologic biomarker findings in a study of mFOLFOX6 plus pembrolizumab (Keytruda) in colorectal cancer.

Management of Metastatic Colon Cancer

Considering data from the real-world setting is becoming increasingly important with the use of anticancer agents, as there is likely a big difference between patients in a clinical trial and patients in the real world, said Juan Manuel O’Connor, MD. During the 2018 ESMO Congress, O'Connor presented real-world dosing findings for regorafenib in patients with metastatic colorectal cancer.

During a presentation at the 2018 International Society of Gastrointestinal Oncology Annual Meeting,&nbsp;Dustin Deming, MD, discussed treatment options showing promise for patients with&nbsp;<em>BRAF</em> V600E&ndash;mutant metastatic colorectal cancer.

Anthony F. Shields, MD, PhD, discusses pivotal data from the IDEA pooled analysis, consisting of 6 international, noninferiority, phase III colon cancer studies.

Al B. Benson III, MD, FACP, FASCO,&nbsp;discusses the treatment landscape for advanced and metastatic CRC and how molecular profiling can play a vital role in selecting the optimal treatment plan for each patient. He also emphasizes the importance of participation in clinical trials to further understand these patients.

Hendrik-Tobias Arkenau, MD, PhD, discusses the rationale for using TAS-102 (trifluridine/tipiracil; Lonsurf) as a treatment for patients with gastric cancers.

James L. Wade III, MD, FACP, FASCO, discusses the importance of clinical trials in the community.